Its constitutive or aberrant activation is a feature of a variety of solid tumors, including colorectal cancer where the NF-κB-signaling pathway functions as a key regulator of cell proliferation, apoptosis, angiogenesis, inflammation, metastasis, and drug resistance, suggesting that NF-κB inhibitors could be helpful in cancer therapies [49,50]. This evidence concerns the gene NFKB1 and cancer.